Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive August 1, 2014	EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire? Industry's grand vision for reshaping the life sciences in Europe may ultimately prove to be a lost cause.
Pharmaceutical Executive July 1, 2005 Sarah Houlton	Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one.
Pharmaceutical Executive July 1, 2011	Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy.
Pharmaceutical Executive October 1, 2012 Peter O'Donnell	Richard Bergstrom -- Europe's Medicine Man The new head of the European Federation of Pharmaceutical Industries and Associations faces a Promethean challenge: selling the merits of costly science and innovation in an era of bristling competition, fiscal crisis, and declining demographics.
Pharmaceutical Executive August 1, 2013	Pharma Bids for European Funding in New Research Program The euro 70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
Pharmaceutical Executive October 1, 2014 William Looney	IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today.
Chemistry World July 10, 2012	Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place.
The Motley Fool June 24, 2010 Luke Timmerman	Amylin Cuts 60 Jobs The pharmaceutical company says research is still a priority.
Pharmaceutical Executive February 1, 2012	Industry/Gov't R&D Support: So Far So Good The EU's Innovative Medicines Initiative is helping to invigorate new drug development, but there are still many hurdles to tackle before its promise is realized.
Pharmaceutical Executive May 1, 2012	Government: Big Pharma's Best Friend in Emerging Markets? To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.
Chemistry World October 1, 2012 Andrew Turley	Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive May 1, 2011	Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement.
Pharmaceutical Executive December 1, 2011	Europe's Transparency Directive Revisited The effect on pharma of the EU's Transparency Directive has been overly constraining, but will the mooted revisions offer any room to maneuver?
Pharmaceutical Executive September 1, 2012	Patients Wade Into the Pricing Debate Europe's fiscal crisis is becoming a new rallying cry for patient groups, but regional unity is still elusive.
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Pharmaceutical Executive February 1, 2013	Country Report: Australia In some ways the Australian medicines industry is going through the same restructuring and challenges as the industry is globally.
Pharmaceutical Executive April 1, 2011	Dalli's Formula Fails the Efficacy Test EU leadership on pharma policy leaves many wondering of the right man is at the helm.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Chemistry World June 23, 2010 Sarah Houlton	A smaller future for big pharma? Cutting the amount spent on medicines may be an easy way for governments to help balance the books in the short term, but in the long run it will impact the ability to discover new medicines.
Chemistry World August 17, 2015 Anthony King	Greek crisis puts pressure on pharmaceuticals Supplies of critical drugs to Greek pharmacies have become sparse and erratic as the economic crisis squeezes public spending
Pharmaceutical Executive June 1, 2014	Hopes High as EU Heads Into Leadership Change The principal drug industry associations in Europe launched a call in mid-May for "an integrated European industrial policy for the pharmaceuticals sector."
Pharmaceutical Executive January 1, 2007 Glass & Poli	Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges.
Pharmaceutical Executive February 1, 2013 Julian Upton	Turkey: A Promise Restored? After a decade of strife, the dialogue between industry and government appears to have entered a positive new phase.
Pharmaceutical Executive September 1, 2014 William Looney	Ireland's Celtic Tiger: Back on the Hunt Leaders from industry, government, and the CRO community examine Ireland's future as a magnet for life science investments, and what the nation must do to remain the leading exporter of finished pharmaceutical products.
Pharmaceutical Executive May 1, 2007	Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive May 1, 2007 Sarah Houlton	Global Report: Pure and Simple The european union is set to overhaul the way it monitors drug safety to help make sense of a decentralized system that has been criticized for being ineffective. Will the EC's upcoming drug-safety plan be just what the doctor ordered or end up an indecent proposal?
Chemistry World May 19, 2015 Anthony King	Roadmap to reward pharma for creating new antibiotics unveiled Pharma firms need better incentives to create novel antibiotics to head off an 'apocalyptic scenario' where commonplace infections become deadly once more.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
Pharmaceutical Executive October 1, 2011	The Essential--and Effective--Bureaucrat Fernand Sauer, First Director General, European Medicines Agency, has witnessed the progressive sterilization of innovative research due to a trend toward ever-larger industry concentration.
Chemistry World July 15, 2014 Emma Stoye	Public--private research partnerships to tackle Europe's big problems The European Union will invest euro 7.3 billion in seven newly launched public -- private partnerships as part of its Horizon2020 research funding program.
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
Pharmaceutical Executive October 1, 2014	Eruptions on the Drug-Pricing Horizon in Europe An escalating political debate over pharma pricing and reimbursement nears the boiling point.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Chemistry World March 16, 2007	Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London.
Pharmaceutical Executive May 1, 2007 Peter Pitts	Opinion: Are Price Controls the New Black? A revamped version of an old bill calling for drug importation is on the congressional runway. With bipartisan backing and red-hot Rahmed-up rhetoric, the legislation might just pass -- and spell failure for the future of innovative drug development.
Chemistry World December 10, 2012 Andrew Turley	EU companies increasing R&D Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors.
Pharmaceutical Executive November 1, 2008 Sarah Houlton	Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
Pharmaceutical Executive January 1, 2012 Jill Wechsler	New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation.
Pharmaceutical Executive September 1, 2013	T-TIPing the Balance in Industry's Favor By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
Bio-IT World December 10, 2002 Malorye Branca	The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D.